Therapeutic Area | MeSH |
---|---|
nervous system diseases | D009422 |
immune system diseases | D007154 |
Brand Name | Status | Last Update |
---|---|---|
mayzent | New Drug Application | 2025-06-18 |
Expiration | Code | ||
---|---|---|---|
SIPONIMOD FUMARIC ACID, MAYZENT, NOVARTIS | |||
2025-03-01 | M-274 | ||
2024-03-26 | NCE |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Multiple sclerosis | D009103 | EFO_0003885 | G35 | — | — | 1 | 1 | 10 | 12 |
Sclerosis | D012598 | — | — | — | — | 1 | 1 | 10 | 12 |
Chronic progressive multiple sclerosis | D020528 | EFO_0003840 | — | — | — | — | 1 | 7 | 8 |
Neoplasm metastasis | D009362 | EFO_0009708 | — | — | — | — | 1 | 5 | 6 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Relapsing-remitting multiple sclerosis | D020529 | EFO_0003929 | — | — | — | 1 | — | 1 | 2 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Alzheimer disease | D000544 | EFO_0000249 | F03 | — | 1 | — | — | — | 1 |
Cognitive dysfunction | D060825 | — | G31.84 | — | 1 | — | — | — | 1 |
Drug common name | Siponimod fumaric acid |
INN | siponimod |
Description | Siponimod, sold under the brand name Mayzent, is a selective sphingosine-1-phosphate receptor modulator for oral use that is used for multiple sclerosis (MS). It is intended for once-daily oral administration.
|
Classification | Small molecule |
Drug class | immunomodulators |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | CCc1cc(/C(C)=N/OCc2ccc(C3CCCCC3)c(C(F)(F)F)c2)ccc1CN1CC(C(=O)O)C1.CCc1cc(/C(C)=N/OCc2ccc(C3CCCCC3)c(C(F)(F)F)c2)ccc1CN1CC(C(=O)O)C1.O=C(O)/C=C/C(=O)O |
PDB | — |
CAS-ID | 1230487-00-9 |
RxCUI | — |
ChEMBL ID | CHEMBL4298150 |
ChEBI ID | — |
PubChem CID | 44599207 |
DrugBank | DB12371 |
UNII ID | RR6P8L282I (ChemIDplus, GSRS) |